NCT06048926View on ClinicalTrials.gov

Carrelizumab Combined With Concurrent Radiotherapy and Chemotherapy for Unresectable Esophageal Squamous Cell Carcinoma

NAEnrolling by invitationINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

July 30, 2022

Primary Completion Date

July 30, 2025

Study Completion Date

July 30, 2028

Conditions
Esophageal Squamous Cell Carcinoma
Interventions
DRUG

Carrelizumab

200 mg/time, iv, Q3W

DRUG

Paclitaxel injection

50mg/m2,iv, D1, 8, 15, 22, 29, once a week, a total of 5 times

DRUG

Cisplatin

25mg/m2，iv， D1、8、15、22、29，once a week, a total of 5 times

RADIATION

Concurrent chemoradiotherapy

Radiotherapy was given simultaneously at the time of the first dose, and the total dose of radiotherapy was 50.4 Gy, which was completed in 28 divided doses of 1.8 Gy each time, 5 times a week.

Trial Locations (1)

Unknown

The First Affiliated Hospital of Nanjing Medical University, Nanjing

All Listed Sponsors
lead

The First Affiliated Hospital with Nanjing Medical University

OTHER